SCHEMBL16009339

SCHEMBL16009339

COc1ccc2[nH]c3ccnc(Cl)c3c2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.57
MEN1 O00255 3/20 0.57
MAPT P10636 3/20 0.57
KMT2A Q03164 3/20 0.57
ALDH1A1 P00352 2/20 0.57
HSD17B10 Q99714 2/20 0.57
TSHR P16473 1/20 0.57
GFER P55789 1/20 0.57
ACHE P22303 2/20 0.56
DYRK1A Q13627 1/20 0.55
POLB P06746 2/20 0.53
CHUK O15111 1/20 0.51
BRD4 O60885 6/20 0.51
BRD2 P25440 5/20 0.50
BRD3 Q15059 5/20 0.50
HPGD P15428 1/20 0.50
BCHE P06276 1/20 0.47
TLR3 O15455 1/20 0.46
NR3C1 P04150 1/20 0.46
KIT P10721 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL613967 0.80 KDM4E (0.63) KDM4EMEN1MAPTKMT2AALDH1A1
SCHEMBL7218007 0.79 AURKA (0.65) KDM4EMEN1MAPTKMT2AALDH1A1
SCHEMBL16010482 0.79 DYRK1A (0.51) KDM4EMEN1KMT2AALDH1A1HSD17B10
SCHEMBL28371682 0.78 KDM4E (0.51) KDM4EMEN1MAPTKMT2AALDH1A1
SCHEMBL16156577 0.77 ERBB2 (0.49) CHUKBRD4BRD2BRD3HPGD
SCHEMBL16009074 0.76 BRD4 (0.63) MEN1MAPTKMT2AALDH1A1DYRK1A
SCHEMBL10547492 0.76 KDM4E (0.56) KDM4EMEN1MAPTKMT2AALDH1A1
SCHEMBL29391519 0.75 ALDH1A1 (1.00) KDM4EMEN1MAPTKMT2AALDH1A1
SCHEMBL2597652 0.75 ALDH1A1 (1.00) KDM4EMEN1MAPTKMT2AALDH1A1
SCHEMBL31451634 0.75 KDM4E (0.58) KDM4EMEN1MAPTKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10391175-B2 BET bromodomain inhibitors and therapeutic methods using the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2019-08-27 US disclosed
US-10391175-B2 BET bromodomain inhibitors and therapeutic methods using the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2019-08-27 US disclosed
EP-2970312-B1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME UNIV MICHIGAN REGENTS (US) 2017-11-15 EP disclosed
EP-2970312-B1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME UNIV MICHIGAN REGENTS (US) 2017-11-15 EP disclosed
US-20170281773-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-10-05 US disclosed
US-20170281773-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-10-05 US disclosed
US-9675697-B2 BET bromodomain inhibitors and therapeutic methods using the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-06-13 US disclosed
US-9675697-B2 BET bromodomain inhibitors and therapeutic methods using the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-06-13 US disclosed
EP-2970312-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME The Regents of The University of Michigan (US) 2016-01-20 EP disclosed
WO-2014164596-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-10-09 WO disclosed
WO-2014164596-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-10-09 WO disclosed
US-20140256706-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10391175-B2 BET bromodomain inhibitors and therapeutic methods using the same BRD4, BRDT, BRD3 KDM4E 580/4885MEN1 3205/4885MAPT 2244/4885
US-20170281773-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME BRD4, BRDT, BRD3 KDM4E 580/4885MEN1 3205/4885MAPT 2244/4885
US-20140256706-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME BRD4, BRDT, BRD3 KDM4E 580/4885MEN1 3205/4885MAPT 2244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.